Premium
Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma: clinicopathological features
Author(s) -
Dal Cin Paola,
Sciot Raf,
Panagopoulos Ioannis,
Åman Pierre,
Samson Ignace,
Mandahl Nils,
Mitelman Felix,
Van Den Berghe Herman,
Fletcher Christopher D. M.
Publication year - 1997
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/(sici)1096-9896(199708)182:4<437::aid-path882>3.0.co;2-x
Subject(s) - myxoid liposarcoma , chromosomal translocation , fusion gene , liposarcoma , gene , biology , chop , pathogenesis , polymerase chain reaction , clinical significance , cancer research , pathology , sarcoma , genetics , lymphoma , medicine , immunology
It is well established that the majority of myxoid/round cell liposarcomas (LPS) are characterized by a reciprocal translocation t(12;16)(q13;p11) which at the molecular level results infusion of the CHOP and FUS/TLS genes. It is assumed that functional characterization of these genes may provide insight into the molecular pathogenesis of this tumour type. This study describes two new cases of myxoid/round cell LPS having a t(12;22). By reverse transcription‐polymerase chain reaction (RT‐PCR) it has been shown that this leads to fusion between the CHOP and EWS genes, thus indicating involvement of the EWS gene, at least occasionally, in yet another sarcoma type. Combining these two cases with two others which were recently similarly characterized at the molecular level, their clinicopathological features have been compared with cases having the more usual t(12;16). It was not possible to identify any clinical or pathological differences between these molecular genetic subsets. The relevance or significance of these gene fusion products in myxoid/round cell LPS remains to be determined. © 1997 John Wiley & Sons, Ltd.